Stocks and Investing
Stocks and Investing
Wed, April 28, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yigal Nochomovitz Maintained (ALDX) at Strong Buy with Increased Target to $25 on, Apr 28th, 2021
Yigal Nochomovitz of Citigroup, Maintained "Aldeyra Therapeutics, Inc." (ALDX) at Strong Buy with Increased Target from $22 to $25 on, Apr 28th, 2021.
Yigal has made no other calls on ALDX in the last 4 months.
There are 2 other peers that have a rating on ALDX. Out of the 2 peers that are also analyzing ALDX, 0 agree with Yigal's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Yigal
- Marc Goodman of "SVB Leerink" Initiated at Buy and Held Target at $22 on, Friday, March 12th, 2021
- Edwin Zhang of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $26 on, Monday, February 8th, 2021
Contributing Sources